Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Decline in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 43,700 shares, a decline of 65.3% from the November 30th total of 125,800 shares. Based on an average daily volume of 1,060,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.5% of the company’s shares are short sold.

Revelation Biosciences Price Performance

Shares of REVB stock traded up $0.05 during mid-day trading on Thursday, hitting $0.35. The stock had a trading volume of 2,558,001 shares, compared to its average volume of 955,570. Revelation Biosciences has a 12-month low of $0.28 and a 12-month high of $25.26. The firm’s 50-day moving average is $0.68 and its two-hundred day moving average is $1.12. The firm has a market capitalization of $1.49 million, a P/E ratio of -0.02 and a beta of 0.15.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.